LNP1 Inhibitors
LNP1 inhibitors form a diverse class of chemicals targeting specific signaling pathways crucial for the activation of LNP1. These inhibitors act at various points in the molecular cascade, disrupting phosphorylation events and protein-protein interactions necessary for LNP1 functionality. Gefitinib, Sunitinib, and Erlotinib target EGFR, a receptor tyrosine kinase associated with LNP1 signaling, disrupting downstream events. BAY 80-6946, Wortmannin, and LY294002 inhibit PI3K, affecting the PI3K/Akt pathway linked to LNP1 activation. Trametinib and U0126 target MEK, disrupting the MAPK/ERK pathway involved in LNP1 activation. AZD8055 and Rapamycin inhibit mTOR, influencing downstream events associated with LNP1. Dasatinib is a multi-kinase inhibitor impacting LNP1 signaling pathways. SB203580 inhibits p38 MAP kinase, affecting pathways related to LNP1 activation. Collectively, these inhibitors provide a comprehensive toolkit for investigating and modulating LNP1 functionality at the molecular level, offering potential insights into the regulatory mechanisms of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits EGFR, a receptor tyrosine kinase linked to LNP1 signaling. Its action disrupts the downstream events associated with LNP1 activation, suppressing its functionality. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
BAY 80-6946 inhibits PI3K, disrupting the PI3K/Akt pathway associated with LNP1 activation. Its interference with this pathway leads to inhibition of LNP1 functionality. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including those linked to LNP1 signaling. Its action disrupts the downstream events associated with LNP1 activation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK, a kinase in the MAPK/ERK pathway associated with LNP1 activation. Its action disrupts downstream events, suppressing LNP1 functionality. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 inhibits mTOR, a key player in the PI3K/Akt/mTOR pathway associated with LNP1 activation. Its action disrupts the pathway, suppressing LNP1 functionality. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, disrupting the PI3K/Akt pathway associated with LNP1. By inhibiting PI3K, it interferes with the activation of LNP1, impacting its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, blocking the MAPK/ERK pathway, which is implicated in LNP1 activation. Its interference with this pathway inhibits LNP1 functionality. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits multiple kinases, including those linked to LNP1 signaling. Its action disrupts the downstream events associated with LNP1 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 targets PI3K, an upstream molecule in the PI3K/Akt pathway linked to LNP1 signaling. Inhibiting PI3K disrupts the activation of LNP1, impacting its functionality. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, a protein involved in pathways related to LNP1. Its action disrupts the downstream events associated with LNP1 activation. | ||||||